AU715997B2 - A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions - Google Patents

A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions Download PDF

Info

Publication number
AU715997B2
AU715997B2 AU63534/96A AU6353496A AU715997B2 AU 715997 B2 AU715997 B2 AU 715997B2 AU 63534/96 A AU63534/96 A AU 63534/96A AU 6353496 A AU6353496 A AU 6353496A AU 715997 B2 AU715997 B2 AU 715997B2
Authority
AU
Australia
Prior art keywords
growth hormone
formulation
calcium ions
solution
treated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU63534/96A
Other versions
AU6353496A (en
Inventor
Per Balschmidt
Thorkild Christensen
Ole Hvilsted Olsen
Hans Holmegaard Soerensen
Lars Thim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU6353496A publication Critical patent/AU6353496A/en
Application granted granted Critical
Publication of AU715997B2 publication Critical patent/AU715997B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Description

WO 97/03692 PCT/DK96/00293
TITLE
A STABILIZED PHARMACEUTICAL FORMULATION COMPRISING A GROWTH HORMONE PRE-TREATED WITH ZINC AND OPTIONALLY LYSINE OR CALCIUM IONS FIELD OF THE INVENTION The present invention relates to a stabilized pharmaceutical formulation comprising growth hormone, to a method of making such formulation, to the use of zinc for stabilizing a formulation of growth hormone, and to a method for treating a disorder affectable by growth hormone.
BACKGROUND OF THE INVENTION The growth hormones from man and from the common domestic animals are proteins of approximately 191 amino acids, synthesized and secreted from the anterior lope of the pituitary gland. Human growth hormone consists of 191 amino acids.
Growth hormone is a key hormone involved in the regulation of not only somatic growth, but also in the regulation of metabolism of proteins, carbohydrates and lipids. The major effect of growth hormone is to promote growth.
The organ systems affected by growth hormone include the skeleton, connective tissue, muscles, and viscera such as liver, intestine, and kidneys.
Until the development of the recombinant technology and the cloning of the growth hormone gene now giving rise to production of e.g. human growth hormone (hGH) and Met-hGH in industrial scale, human growth hormone could only be obtained by extraction from the pituitary glands of human cadavers. The very limited supplies of growth hormone restricted the use thereof to longitudinal growth promotion in childhood and puberty for treatment of dwarfism, even WO 97/03692 PCT/DK96/00293 2 though it has been proposed for inter alia treatment of short stature (due to growth hormone deficiency, normal short stature and Turner syndrome), growth hormone deficiency in adults, infertility, treatment of burns, wound healing, dystrophy, bone knitting, osteoporosis, diffuse gastric bleeding, and pseudoarthrosis.
Furthermore, growth hormone has been proposed for increasing the rate of growth of domestic animals or for decreasing the proportion of fat in animals to be slaughtered for human consumption.
Pharmaceutical formulations of growth hormone tend to be unstable. Degradation products such as deamidated or sulfoxydated products and dimer or polymer forms are generated especially in solutions of growth hormone.
The predominant degradation reactions of hGH are 1) deamidation by direct hydrolysis or via a cyclic succinimide intermediate to form various amounts of L-asp-hGH, L-isoasp-hGH, D-asp-hGH, and D-iso-asp-hGH (ref and 2) oxidation of the methionine residues in positions 14 and 125 (ref The major degradation product of hGH in lyophilized state as well as in solution is deamidated hGH.
Deamidation especially takes place at the Asn in position 149 and to a minor extent in position 152.
hGH is also rather easily oxidized in positions 14 and 125.
The oxidation of hGH in solution forming sulfoxides is normally due to the oxygen dissolved in the formulation. The solubility of oxygen in distilled water is about 200 M As the concentration of hGH in a formulation comprising 4 IU/ml is 1.3 mg/ml corresponding to 60nM hGH, oxygen will, at normal storing conditions, be present in an excess of about 3000 times the stoichiometric amount for oxidation of WO 97/03692 PCT/DK96/00293 3 hGH. It is not feasible to try to solve the problem by degassing of buffers before tapping and packing the formulations.
At present, it is not believed that these deamidated forms and oxidized forms of hGH should have toxic or altered biological activity or receptor binding properties, but there is indication to the effect that the conformation stability of the sulfoxides is reduced as compared to native hGH.
For the development of a stable, dissolved formulation comprising hGH it is of importance to know the rate of deamidation and formation of sulfoxides as well as means to control the reactions.
The kinetics of degradation depend on temperature, pH and various additives or adjuvants in the hGH formulation.
Due to the instability, growth hormone is, at present, lyophilized and stored in the lyophilized form at 4 0 C until it is reconstituted for use in order to minimize the degradation.
The lyophilized pharmaceutical formulations comprising hGH are, at present, reconstituted by the patient and then stored as a solution during the use for a period of up to 14 days at 4 0 C, during which some degradation will take place.
Furthermore, the process of reconstitution of the lyophilized growth hormone tends to provide difficulties for the patient.
Thus, it is at present preferred to reconstitute the growth hormone as late as possible before use and to store and ship the formulation in a lyophilized state. The chain from the WO 97/03692 PCT/DK96/00293 4 manufacturer to the pharmacy is apt for handling the formulations at a controlled low temperature of e.g. which allows for a long shelf life of up to two years.
However, the extended use of pen systems for self-medication and the expanded field of use calls for a formulation which is stable for a sufficient long time with the end user under conditions where "sufficient" cooling is not always available.
Preferably, a formulation should be stable with the end user in a lyophilized state for about one month and additionally for one month in a reconstituted state in a pen device for the intended period of use of a cartridge.
Thus, there is a need for more stable formulations of growth hormone being stable in a lyophilized state at a relative high temperature for a period and additionally for a period of use at a relatively high temperature in solution. Such stabilization is of very great importance when moving the administration of the growth hormone from clinics to the homes of the individuals to be treated where optimal storage may not be available as indicated above.
Furthermore, the shift in pattern of administration of growth hormone to the use of pen devices calls for a stable dissolved formulation comprising growth hormone in order to facilitate the handling to be performed by the patient. A stable dissolved formulation comprising growth hormone may be produced ready to use in the form of cartridges fitting into the pen device used by the patient who may then avoid the reconstitution of the formulation and, hence, will not have to be in the possession of a lyophilized formulation, a suitable vehicle for reconstitution as well as the necessary skill and sterile equipment for sterile reconstitution of the formulation.
WO 97/03692 PCT/DK96/00293 For safety reasons it will also be desirable to avoid the reconstitution of a lyophilized formulation just before the use of the formulation.
Furthermore, it would also be an advantage to avoid the lyophilization step in the production of growth hormone formulations. Lyophilization is a time consuming and costly process and is also often a "bottleneck" in the production due to the limited capacity of the freeze drier.
Thus, there is a need to reduce the rate of the degradation processes in order to allow for dissolved hGH formulations being stable during shelf life and during the period of use of up to one month.
Prior attempts to stabilize hGH has not fully succeeded in preventing the formation of dimer. The problems associated with dimer formation is e.g noted in Becker, Biotechnology and Applied Biochemistry 9, 478 (1987) International Patent Publication No. WO 89/09614 and Australian patent application No. 30771/89 disclose a stable pharmaceutical formulation containing human growth hormone, glycine, and mannitol. Such a formulation shows improved stability during normal processing and storage in a lyophilized state as well as in the period of use after the reconstitution.
Published European patent application No. 303 746 discloses that animal growth hormone may be stabilized with various stabilizers to give decreased formation of insolubles and preservation of the soluble activity in aqueous environments, such stabilizers including certain polyols, amino acids, polymers of amino acids having a charged side group at physiological pH, and choline salts. Polyols are selected from the group consisting of non-reducing sugars, WO 97/03692 PCT/DK96/00293 6 sugar alcohols, sugar acids, pentaerythritol, lactose, water-soluble dextrans and Ficoll; amino acids are selected from the group consisting of glycine, sarcosine, lysine or salts thereof, serine, arginine or salts thereof, betaine, N,N,-dimethyl-glycine, aspartic acid or salts thereof, glutamic acid or salts thereof; a polymer of an amino acid having a charged side group at physiological pH may be selected from polylysine, polyaspartic acid, polyglutamic acid, polyarginine, polyhistidine, polyornithine and salts thereof; and choline derivatives are selected from the group consisting of choline chloride, choline dihydrogen citrate, choline bitartrate, choline bicarbonate, tricholine citrate, choline ascorbate, choline borate, choline gluconate, choline phosphate, di(choline)sulphate and dicholine mucate.
US patent specification No. 4,917,685 discloses a delivery device designed to be implanted comprising growth hormone stabilized using the same stabilizers as mentioned in EP 303746.
Published European patent application No. 374,120 discloses a stabilized formulation comprising hGH and a polyol having three hydroxy groups. Glycerol and tris(hydroxymethyl)aminomethane are mentioned. Furthermore, the presence of histidine hydrochloride as a buffer together with the polyol is disclosed.
International Patent Publication No. WO 92/00998 discloses that crystals may be formed crystallizing growth hormone with zinc.
International Patent Publication No. WO 93/12811 discloses stabilized formulations of growth hormone in the form of a lyophilized powder or an aqueous solution comprising asparagine.
WO 97/03692 PCT/DK96/00293 7 International Patent Publication No. WO 93/12812 discloses stabilized formulations of growth hormone in the form of a lyophilized powder or an aqueous solution comprising histidine. In such formulations the deamidation is reduced by 30% as compared to a corresponding formulation of growth hormone comprising phosphate buffer. Furthermore, it 'is disclosed that crystals may be formed crystallizing growth hormone with zinc in the presence of histidine.
International Patent Publication No. WO 93/19776 discloses protein formulations comprising growth hormone comprising citrate as buffer substance being more stable than formulations comprising phosphate buffer. The formulations may also comprise amino acids such as glycine and alanine and/or mannitol or other sugar alcohols and/or glycerol and/or other carbohydrates and optionally a preservative such as benzyl alcohol.
International Patent Publication No. WO 94/03198 discloses a stable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative.
Published European patent application No. 177,478 discloses a prolonged release composition comprising zinc and somatotropin in a continuous phase with a biocompatible oil.
Published European patent application No. 216,485 discloses a sustained-release composition comprising zinc and somatotropin in a vehicle comprising a vegetable oil and an adjuvant, especially beeswax, aluminum monostearate, carnauba wax or paraffin.
Published European patent application No. 277,043 discloses recovering somatotropin from an aqueous solution by adding a salt of a transition metal and precipitation of an insoluble complex.
International Patent Publication No. WO 93/13792 discloses a delayed release implantable device comprising a somatotropin and zinc and optionally a basic side group containing amino acid solubilising Zn-somatotropin, arginine, alanine, histidine and glutamic acid being mentioned as examples of amino acids.
International Patent Publication No. WO 92/17200 discloses stable growth hormone metal ion formulations in the form of dimers showing stability to denaturation. The formulations may comprise glycine and optionally additionally alanine, glutamine, asparagine, arginine or lysine, such amino acids being particularly advantageous when lyophilising the formulation to create a sufficient mass to form a stable, dry caked formulation.
Brief Description of the Invention It has now surprisingly been found that a formulation of human growth hormone pretreated for at least one hour with zinc salt and optionally lysine or calcium ions before preparation of the final formulation shows a very high stability against deamidation in 15 aqueous solution and is furthermore readily dissolvable in aqueous solvents when lyophilised. The stability of the product allows for the storing and shipment thereof in a lyophilised state or in the form of a dissolved or re-dissolved formulation.
The pharmaceutical formulations of the invention may be formulated for administration in any suitable way, e.g. by parenteral or oral administration or administration to a mucosal membrane, e.g. nasal administration. The pharmaceutical formulation may be presented in the form of a dose comprised in a vial or cartridge or any other suitable container such as a prefilled syringe or a pen device.
SThus, the formulation of the invention may be in the form of a lyophilised powder to be reconstituted later using conventional vehicles such as distilled water or water for injection or in the form of a solution comprising growth hormone. Such vehicles may comprise conventional preservatives such as phenol, m-cresol and benzyl alcohol.
A preferred embodiment of the invention is in the form of a pharmaceutical formulation of human growth hormone pre-treated for at least one hour with zinc salt and optionally lysine or calcium ions and further comprising a carrier in the form of a buffered aqueous solution of growth hormone. Such formulation is in a ready-to-use form and may be stored and shipped as an aqueous solution without any considerable degradation.
[R:\LIBAA]07767.doc:tab A buffer to be used in a solution ofpre-treated growth hormone may e.g. be histidine, citrate, tartrate or phosphate buffer. Preferably, the buffer is histidine buffer.
The pre-treatment solution is preferably adjusted to a value in the interval from about 2 to about 9, more preferred to pH from 6 to 8, especially to about 7 to 7.3.
For stability reasons the pH in the final formulation of pre-treated growth hormone is preferably adjusted to a value of about 2 to about 9, more preferred to a value of about 6 to about 8, especially to a value of about 6.0 to about 6.8.
In order to obtain the stabilising effect of zinc and optionally lysine or calcium ions zinc is preferably added in an amount of up to 2mM, preferably from about 1 to about 4 0o moles Zn per mol of growth hormone, preferably about 1 to 2 moles Zn per mole growth hormone, most preferred about 1 mol Zn per mol growth hormone.
Zinc is preferably added in the form of a physiologically acceptable soluble salt such as the chloride.
Calcium ions when present are preferably added in the form of a physiologically 15 acceptable soluble salt such as the chloride.
The pharmaceutical formulation of the invention may furthermore comprise salts or sugar alcohols for adjusting the tonicity and optionally an excipient in order to facilitate the processing thereof, e.g. lyophilisation and the rapid and complete dissolution of a lyophilised formulation when reconstituting the formulation before use.
20 An excipient may be selected from disaccharides such as lactose, trehalose, and sucrose, sugar alcohols such as sorbitol or mannitol, polysaccharides such as the polymers S. commercialised as Dextran® products such as Dextran® 40, Dextran® 70 or Dextran® and Ficoll® and polyvalent alcohols such as polyethylene glycol or polyvinyl alcohol or a combination of two or more of these.
In a further aspect the invention relates to a method of preparing a pharmaceutical formulation comprising a growth hormone pre-treated with zinc salt and optionally lysine or calcium ions, the method comprising dissolving the growth hormone in a solution comprising zinc chloride and optionally lysine or calcium ions, letting the solution of (a) stand for at least one hour, and adding benzyl alcohol to the solution of step and (d) optionally adjusting the pH from about 2 to about 9.
[R:\LIBAA]07767.doc:tab The pH may be adjusted by adding an acid which has no adverse effect on the growth hormone, preferably a physiologically acceptable acid e.g. a mineral acid such as hydrochloric acid, sulphuric acid or nitric acid or an organic acid such as acetic acid.
.99 S. 9 9
S
9S S 9 5.5 9 9* *5 9 9
S
9
S
9999 S9 S S 9959 9 S 9 .9 9 9* 9 9* 9 *5599* 9 *.99 9 9 [R:\LIBAA]07767.doc:tab WO 97/03692 PCT/DK96/00293 11 In an embodiment of the method of the invention, is added optionally salts and an excipient, whereafter the solution is filled into a container and lyophilized.
Still another aspect of the invention relates to the use of zinc and optionally lysine or calcium ions for pre-treatment of growth hormone for the formulation of a stabilized formulation of growth hormone.
In yet another aspect the invention relates to a method for treating a disorder affectable by growth hormone comprising administering a formulation which comprises a growth hormone pre-treated with zinc and optionally lysine or calcium ions.
In the present context "growth hormone" may be growth hormone from any origin such as avian, bovine, equine, human, ovine, porcine, salmon, trout or tuna growth hormone, preferably bovine, human or porcine growth hormone, human growth hormone being most preferred. The growth hormone used in accordance with the invention may be native growth hormone isolated from a natural source, e.g. by extracting pituitary glands in a conventional manner, or a growth hormone produced by recombinant techniques, e.g as described in E.B. Jensen and S. Carlsen in Biotech and Bioeng. 36, 1- 11 (1990). The "growth hormone" may also be a truncated form of growth hormone wherein one or more amino acid residues has (have) been deleted; an analogue thereof wherein one or more amino acid residues in the native molecule has (have) been substituted by another amino acid residue, preferably a natural amino acid residue, as long as the substitution does not have any adverse effect such as antigenicity or reduced action; or a derivative thereof, e.g having an N- or Cterminal extension such as Met-hGH. The preferred growth hormone is hGH.
WO 97/03692 PCT/DK96/00293 12 The term "dose" of growth hormone refers to that amount that provides therapeutic effect in an administration regimen.
The formulations hereof are prepared containing amounts of hGH at least about 0.1 mg/ml, preferably upwards of about mg/ml, preferably from about 1 mg/ml to about 40 mg/ml, more preferably from about 1 mg/ml to about 25 mg/ml, e.g. from 1 mg/ml to about 5 mg/ml, calculated on the ready-to-use formulation. For use of these compositions in administration to human beings suffering from hypopituitary dwarfism, for example, these formulations contain from about 0.1 mg/ml to about 10 mg/ml, corresponding to the currently contemplated dosage regimen for the intended treatment. The concentration range is not critical to the invention and may be varied by the physician supervising the administration.
Lysine to be used in accordance with the present invention is preferably the naturally occurring alpha amino acid. The lysine may be 1 or d lysine or a mixture thereof.
In the present context "high stability" is obtained when the formulation is more stable than the conventional formulation comprising phosphate buffer and preferably as stable as a corresponding formulation comprising histidine as stabilizer in which the deamidation of hGH is reduced by approximately 20% as compared with phosphate buffer as disclosed in WO 93/12812.
The solvent used in the method of the invention may be water, alcohols such as ethyl, n-propyl or isopropyl, butyl alcohol or mixtures thereof. The solvent may comprise a preservative such as phenol, m-cresol or benzyl alcohol.
WO 97/03692 PCT/DK96/00293 13 The term "pre-treated" is used in the present context in connection with growth hormone formulations to designate a growth hormone which is treated with zinc and optionally lysine or calcium ions before the addition of or to the further components for preparation of a growth hormone formulation.
DETAILED DESCRIPTION OF THE INVENTION The invention is explained more in detail in the below Examples which illustrate the invention. They are not to be considered as limiting the scope of the invention being defined by the appended claims.
EXPERIMENTAL
PART
EXAMPLE
Reduction of the deamidation.
The rate of deamidation after different pre-treatments was examined at 37 0 C for hGH formulations containing 4 mg/ml hGH, 0.18 mM ZnC1 2 3 mM histidine, 1.5% benzyl alcohol, pH 6.8 as compared to histidine and phosphate buffer at pH 6.8.
The hGH formulations were prepared by dissolving 24 mg hGH in 2.5 ml of a) 2 mM CaC12 2 0.36 mM ZnCl 2 pH 7-7.3, b) 2 mM lysine 0.36 mM ZnCl 2 pH 7-7.3 or c) 0.36 mM ZnCl 2 pH 7-7.3.
After storage 1 h at 4°C (to allow Zn" to complex with hGH) the preparations were reformulated using a desalting column (Pharmacia) into 3 ml 6 mM histidine, 0.36 mM ZnCl 2 8 mg/ml hGH. Thereafter 3 ml 3% benzyl alcohol were added resulting in a final formulation of 4 mg/ml hGH, 3 mM WO 97/03692 PCT/DK96/00293 14 histidine, 0.18 mM ZnCi 2 1.5% benzyl alcohol, (pH adjusted to 6.8 adding HCl/NaOH).
As reference formulations were used a) 4mg/ml hGH, 3 mM histidine, 0.18 mM ZnCl2 1.5% benzyl alcohol, pH 6.8; b) 4mg/ml hGH, 3 mM histidine, 1.5% benzyl alcohol, pH 6.8; and c) 4 mg/ml hGH, 3 mM Na 2
HPO
4 1.5% benzyl alcohol, pH 6.8.
The reference formulations were not pre-treated with Zn".
The hGH formulations stated in the below table were stored at 37 0 C for 7 days, and analyzed for the content of deamidated hGH by IE-HPLC. The results appear from the below table WO 97/03692 PCT/DK96/00293 Formulation PHstart /pHend Content of Content of deamidated deamidated hGH forms as compared with histidi-ne 3 mM histidine,0.18 mM 6.78/6.84 10.0 84 ZnCl 2 1.5% benzyl alcohol, pH 6.8.
Pre-treated in accordance with procedure a) 3 mM histidine,0.18 mM 6.75/6.83 11.3 88 ZnCl 2 1.5% benzyl alcohol, pH 6.8.
Pre-treated in accordance with procedure b) 3 mM histidine,0.18 6.79/6.87 11.5 89 mM ZnCl 2 benzyl alcohol, pH 6.8.
Pre-treated in accordance with procedure c) 3 mM histidine,0.18 mM 6.84/6.92 12.8 99 ZnC1 2 1.5% benzyl alcohol, pH 6.8.
No pre-treatment.
3 mM histidine, 1.5% 6.84/6.92 12.9 100 benzyl alcohol, pH 6.8 3 mM Na 2 HP0 4 1.5% 6.83/6.86 15.9 123 benzyl alcohol, pH 6.8 #Desamido content corrected by 1% per 0.1 pH unit deviation from 6.8.
From the above table it appears that the deamidation rate of hGH is reduced to 84% relative to the histidine (68% relative to the phosphate formulation) when the hGH solution is treated with Zn" in the presence of Ca" or lysine prior to resalting into the final histidine formulation.
WO 97/03692 WO 9703692PCT/DK96/00293
REFERENCES
1) Wang and M.A. Hanson. Parentera.
of Proteins and Peptides: Stability and J. Parenteral Science and Technology (1988) 53-525.
Formulations Stabilizers.
42 (Suppl.) 2) M.C. Manning, K. Patel, R.T. Borchardt. Stability of Protein Pharmaceuticals. Pharmaceutical Research 6 (11) (1989) 903-918.
3) B.A. Johnson, J.M. Shirokawa, W.S. Hancock, M.W.
Spellman, L.J. Basa and D.W. Asward. J.Biol.Chem.
264, 1462-71 (1989).
4) L.C. Teh et al., J.Biol.Chem., 262, 785-794 (1987).
G.W. Becker et al., Biotech. Appl. Biochem. 10, 326- 337 (1988).
6) R.A. Houghten et al., Arch.Biochem.Biophys., 178, 350-355 (1977).
7) R.M. Riggin et al., Anal.Biochem., 167, 199-209 (1987).
8) P. Gellerfors et al., Acta Paediatr.Scand (suppl), 370, 93-100 (1990).
9) N.J. Kaufman, Pharm.Res., 7 289-292 (1990).

Claims (14)

1. A formulation comprising a human growth hormone pre-treated for at least one hour with zinc salt and optionally lysine or calcium ions.
2. The formulation according to claim 1, further comprising a carrier in the form of s a buffered aqueous solution.
3. The formulation according to claim 1 or claim 2, wherein said formulation has a pH between about 2 to about 9.
4. The formulation according to any one of the preceding claims, wherein the concentration of zinc salt is between about 0.0 1-2 mM.
5. The formulation according to any one of the preceding claims, further comprising salts and saccharides.
6. A method of preparing the pharmaceutical formulation according to claim 1, the method comprising dissolving growth hormone in a solution comprising zinc chloride and optionally lysine or calcium ions, letting the solution of stand for at least one hour, adding benzyl alcohol to the solution of step and optionally adjusting the "pH to from about 2 to about 9.
7. The method according to claim 6, which further comprises after step and before step reformulating the solution of step by gel filtration chromatography.
8. The method according to claim 6 or claim 7, further comprising adding salts and 20 an excipient, filling the solution into a container and lyophilising said solution.
9. A pharmaceutical formulation comprising a growth hormone pre-treated with zinc salt, and optionally lysine or calcium ions, substantially as hereinbefore described with reference to any one of the Examples.
10. A method of preparing a pharmaceutical formulation comprising a human growth hormone, substantially as hereinbefore described with reference to any one of the Examples.
11. A pharmaceutical formulation prepared by the method of any one of claims 6 to 8 or
12. Use of zinc salt and optionally lysine or calcium ions for pre-treatment of growth hormone for the formulation of a stabilised formulation of growth hormone.
13. A method for treating a disorder affectable by growth hormone deficiency, the method comprising administering the formulation of any one of claims 1 to 5, 9 or 11.
14. A formulation according to any one of claims 1 to 5, 9 or 11 when used in the treatment of a disorder affectable by growth hormone deficiency in a mammal requiring said treatment. [R:\LIBAA]07767.doc:tab 18 The use of a growth hormone pre-treated for at least one hour with zinc salt and optionally lysine or calcium ions for the preparation of a formulation for use in the treatment of a disorder affectable by growth hormone deficiency in a mammal requiring said treatment. Dated 9 December, 1999 Novo Nordisk A/S Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON 9**e 9 9 9 9 [R:\LIBAA]07767,doc:tab
AU63534/96A 1995-07-14 1996-06-28 A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions Ceased AU715997B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US119395P 1995-07-14 1995-07-14
US60/001193 1995-07-14
PCT/DK1996/000293 WO1997003692A1 (en) 1995-07-14 1996-06-28 A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions

Publications (2)

Publication Number Publication Date
AU6353496A AU6353496A (en) 1997-02-18
AU715997B2 true AU715997B2 (en) 2000-02-17

Family

ID=21694837

Family Applications (1)

Application Number Title Priority Date Filing Date
AU63534/96A Ceased AU715997B2 (en) 1995-07-14 1996-06-28 A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions

Country Status (14)

Country Link
EP (1) EP0839049A1 (en)
JP (1) JPH11509212A (en)
KR (1) KR19990028981A (en)
CN (1) CN1190897A (en)
AU (1) AU715997B2 (en)
BR (1) BR9609741A (en)
CA (1) CA2226523A1 (en)
CZ (1) CZ9498A3 (en)
HU (1) HUP9802287A3 (en)
IL (1) IL122583A0 (en)
NO (1) NO980155D0 (en)
PL (1) PL324379A1 (en)
WO (1) WO1997003692A1 (en)
ZA (1) ZA965368B (en)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027980A2 (en) * 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
EP2050762A3 (en) 1998-03-10 2009-07-08 Genentech, Inc. Human cornichon-like protein and nucleic acids encoding it
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
DE69936382T3 (en) 1998-05-15 2011-07-07 Genentech, Inc., Calif. THERAPEUTIC USES OF IL-17 HOMOLOGOUS POLYPEPTIDE
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
DE60043322D1 (en) 1999-06-15 2009-12-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids for their coding
CA2491610A1 (en) 1999-12-01 2001-06-07 Kevin P. Baker Secreted and transmembrane polypeptides and nucleic acids encoding the same
DK1897944T3 (en) 1999-12-23 2011-10-24 Genentech Inc IL-17 homologous polypeptides and their therapeutic use
DE60137829D1 (en) 2000-01-13 2009-04-16 Genentech Inc HUMAN STRA6 POLYPEPTIDE
WO2001062296A2 (en) 2000-02-24 2001-08-30 Monsanto Technology Llc Non-aqueous injectable formulations for extended release of somatotropin
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
AU4935701A (en) 2000-03-24 2001-10-08 Genentech Inc Use of insulin for the treatment of cartilagenous disorders
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001271491A1 (en) 2000-06-26 2002-01-08 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
EP1309312A2 (en) 2000-08-07 2003-05-14 Inhale Therapeutic Systems, Inc. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
ATE412009T1 (en) 2000-08-24 2008-11-15 Genentech Inc METHOD FOR INHIBITING IL-22 INDUCED PAP1
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
SI1485477T1 (en) 2002-02-25 2009-10-31 Genentech Inc Novel type-1 cytokine receptor glm-r
JP4869064B2 (en) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド High concentration antibody and protein preparation
DK1636593T5 (en) 2003-06-06 2009-07-27 Genentech Inc Modulating the interaction between HGF-beta chain and c-met
KR100945327B1 (en) 2003-07-08 2010-03-08 제넨테크, 인크. Il-17a/f heterologous polypeptides and therapeutic uses thereof
US20050233960A1 (en) 2003-12-11 2005-10-20 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
WO2005095450A2 (en) 2004-03-30 2005-10-13 Nsgene A/S Therapeutic use of a growth factor, nsg33
WO2006052468A2 (en) 2004-10-27 2006-05-18 University Of Denver Adrenocorticotropic hormone analogs and related methods
JP2008541781A (en) 2005-06-06 2008-11-27 ジェネンテック・インコーポレーテッド Transgenic animals for different genes and their use for characterizing genes
WO2008018854A2 (en) 2005-06-06 2008-02-14 The Rockefeller University Bactiophage lysins for bacillus anthracis
MX2007016032A (en) 2005-06-21 2008-03-10 Xoma Technology Ltd Il-1 beta binding antibodies and fragments thereof.
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
JP2009504183A (en) 2005-08-15 2009-02-05 ジェネンテック・インコーポレーテッド Gene disruption and related compositions and methods
US8105585B2 (en) 2005-08-24 2012-01-31 The Rockefeller Universtiy Ply-GBS mutant lysins
CA2630432A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
RU2385877C1 (en) 2005-12-22 2010-04-10 Дженентек, Инк. Recombinant production of heparin binding proteins
US7456251B2 (en) 2006-02-02 2008-11-25 Trimeris, Inc. HIV fusion inhibitor peptides with improved biological properties
WO2007114979A2 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
EP2004221A2 (en) 2006-03-23 2008-12-24 Novartis Pharma AG Anti-tumor cell antigen antibody therapeutics
US7695928B2 (en) 2006-04-10 2010-04-13 Genentech, Inc. Disheveled PDZ modulators
US20090288176A1 (en) 2006-04-19 2009-11-19 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
PT2049148T (en) * 2006-07-06 2016-12-30 Daewoong Co Ltd A stable liquid formulation of human growth hormone
EP3124045A3 (en) 2006-12-20 2017-05-03 Xoma (Us) Llc Treatment of il-1 beta related diseases
CN101361968B (en) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 Use of interleukin-22 in treating fatty liver
PL2391650T3 (en) 2007-12-20 2015-03-31 Xoma Us Llc Methods for the treatment of gout
KR20210145307A (en) 2008-08-15 2021-12-01 아이언우드 파마슈티컬스, 인코포레이티드 Linaclotide-containing formulations for oral administration
EP2331077A2 (en) * 2008-09-04 2011-06-15 Ironwood Pharmaceuticals, Inc. Stable forlulation comprising therapeutic polypeptides for oral administration
JP2013501071A (en) * 2009-08-06 2013-01-10 アイロンウッド ファーマシューティカルズ， インコーポレイテッド Formulations containing linaclotide
MX368790B (en) 2009-10-15 2019-10-16 Genentech Inc Chimeric fibroblast growth factors with altered receptor specificity.
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
CN107674121A (en) 2009-12-21 2018-02-09 Ambrx 公司 Bovine somatotropin polypeptide and its purposes by modification
CN104017063A (en) 2009-12-21 2014-09-03 Ambrx公司 Modified porcine somatotropin polypeptides and their uses
KR20120113265A (en) 2010-01-15 2012-10-12 유니버시티 오브 메디신 앤드 덴티스트리 오브 뉴 저지 Use of vanadium compounds to accelerate bone healing
MX340234B (en) 2010-02-17 2016-07-01 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders.
MX354867B (en) 2010-03-22 2018-03-23 Genentech Inc Star Compositions and methods useful for stabilizing protein-containing formulations.
WO2011139718A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations
AU2011270828B2 (en) 2010-06-24 2015-09-24 Genentech, Inc. Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
EP3626253B8 (en) 2010-08-11 2022-04-20 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
CN102380091A (en) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 Application of interleukin-22 in curing virus hepatitis
AU2011307488B2 (en) 2010-10-01 2015-08-20 Hoba Therapeutics Aps Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
JP5913326B2 (en) 2010-10-08 2016-04-27 シャンハイ クーシン バイオテック カンパニー，リミテッド Diagnostic and therapeutic use of moesin fragments
WO2012045274A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Moesin modulators and uses thereof
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
AR086672A1 (en) * 2011-06-02 2014-01-15 Baxter Int RECOMBINANT FURINA FORMULATIONS
MX347354B (en) 2011-08-17 2017-04-24 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders.
EP3091029B1 (en) 2011-10-31 2022-12-28 F. Hoffmann-La Roche AG Anti-il13 antibody formulations
CN104144946A (en) 2011-12-19 2014-11-12 爱克索马美国有限责任公司 Methods for treating acne
CA2863224A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
US20150011431A1 (en) 2012-01-09 2015-01-08 The Scripps Research Institute Humanized antibodies
CA2903091C (en) 2013-03-15 2022-09-06 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
CN105814074B (en) 2013-07-18 2020-04-21 图鲁斯生物科学有限责任公司 Humanized antibodies with ultralong complementarity determining regions
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
CA2924109A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
WO2015057852A1 (en) 2013-10-15 2015-04-23 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
JP6734774B2 (en) 2013-10-15 2020-08-05 ザ スクリプス リサーチ インスティテュート Peptide chimeric antigen receptor T cell switch and uses thereof
CN104623639A (en) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Application of interleukin-22 dimer in preparation of drugs for treating pancreatitis
CN104623637A (en) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Application of IL-22 dimer in preparation of intravenous injection drugs
KR102455171B1 (en) 2013-12-18 2022-10-14 더 스크립스 리서치 인스티튜트 Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
NL2014230B1 (en) 2015-02-04 2016-10-12 Stichting Vu-Vumc Wound healing formulation.
MA41629A (en) 2015-03-04 2018-01-09 Center For Human Reproduction COMPOSITIONS AND METHODS OF USE OF ANTI-MÜLLERIAN HORMONE FOR THE TREATMENT OF INFERTILITY
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
EP3283113A4 (en) 2015-04-15 2018-12-05 The California Institute for Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
US20190000928A1 (en) 2015-06-17 2019-01-03 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
EP3442562B1 (en) 2016-04-15 2022-09-21 Evive Biotechnology (Shanghai) Ltd An il-22 dimer for use in treating necrotizing enterocolitis
CA3040343A1 (en) 2016-10-19 2018-04-26 California Institute For Biomedical Research Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
TW202102266A (en) 2019-04-01 2021-01-16 美商建南德克公司 Compositions and methods for stabilizing protein-containing formulations
CA3149494A1 (en) 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
EP4048405A2 (en) 2019-10-24 2022-08-31 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
CA3217865A1 (en) 2021-04-28 2022-11-03 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
AU2022269279A1 (en) 2021-05-06 2023-11-30 Hoba Therapeutics Aps Prevention and treatment of chemotherapy-induced neuropathic pain
WO2023104960A1 (en) 2021-12-10 2023-06-15 Hoba Therapeutics Aps Treatment of nociceptive pain

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017200A2 (en) * 1991-03-28 1992-10-15 Genentech, Inc. Stable growth hormone metal ion formulations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017200A2 (en) * 1991-03-28 1992-10-15 Genentech, Inc. Stable growth hormone metal ion formulations

Also Published As

Publication number Publication date
JPH11509212A (en) 1999-08-17
HUP9802287A3 (en) 2000-10-30
IL122583A0 (en) 1998-06-15
BR9609741A (en) 1999-03-16
NO980155L (en) 1998-01-13
EP0839049A1 (en) 1998-05-06
PL324379A1 (en) 1998-05-25
AU6353496A (en) 1997-02-18
NO980155D0 (en) 1998-01-13
HUP9802287A2 (en) 1999-02-01
CN1190897A (en) 1998-08-19
MX9800358A (en) 1998-07-31
WO1997003692A1 (en) 1997-02-06
CA2226523A1 (en) 1997-02-06
KR19990028981A (en) 1999-04-15
CZ9498A3 (en) 1998-06-17
ZA965368B (en) 1997-01-14

Similar Documents

Publication Publication Date Title
AU715997B2 (en) A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions
US5851992A (en) Treatment of growth hormone deficiency
US5705482A (en) Pharmaceutical formulation
US20020077461A1 (en) Pharmaceutical formulation
US5654278A (en) Composition and method comprising growth hormone and leucine
US8841252B2 (en) Pharmaceutical formulation
EP0785796B1 (en) A pharmaceutical formulation comprising a growth hormone and isoleucine
US5547696A (en) Pharmaceutical formulation
EP0785797B1 (en) A pharmaceutical formulation comprising a growth hormone and leucine
US6022858A (en) Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5552385A (en) Pharmaceutical formulation
AU4329596A (en) A stabilized pharmaceutical formulation comprising a growth hormone and x-lys
AU6353396A (en) A stabilized pharmaceutical formulation comprising a growth hormone and a peptide comprising at least, one basic amino acid residue and at least one acid amino acid residue
AU4329496A (en) A stabilized pharmaceutical formulation comprising a growth hormone and lys-x
MXPA98000358A (en) Stabilized pharmaceutical formulation comprising a pretracted growth hormone with zincy optionally lysine or ions cal
MXPA98000309A (en) Stabilized pharmaceutical formulation comprising a hormone of growth and a peptide that comprises at least one residue of basic amino acid and at least one waste of aminoacido ac

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired